Skip to main content

Table 2 Prevalence of human papilloma virus (HPV) and vaccine covered genotypes among women

From:Prevalence of vaccine and non-vaccine human papillomavirus types among women in Accra and Kumasi, Ghana: a cross-sectional study

Parameter Frequency* Proportion Proportion Proportion SE 95% CI
(%)a (%)b (%)c Lower Upper
HPV positive 138 43.5 2.9 37.9 48.6
Type of infection
Single 59 18.6 42.8 2.1 14.2 23.0
Multiple 79 24.9 57.2 2.5 20.2 30.6
Risk category
High risk 111 35.0 80.4 2.8 29.6 40.4
Probable high risk 46 14.5 33.3 2.0 10.7 18.3
Low risk 54 17.0 39.1 2.2 12.9 21.2
High-risk HPV genotype
HPV-16 14 4.4 10.1 12.6 1.2 2.2 6.6
HPV-18 13 4.1 9.4 11.7 1.1 2.2 6.3
HPV-31 12 3.8 8.7 10.8 1.1 1.9 6.3
HPV-33 2 0.6 1.4 1.8 0.5 0.0 1.6
HPV-35 17 5.4 12.3 15.3 1.3 2.8 7.9
HPV-39 10 3.2 7.2 9.0 1.0 1.6 5.4
HPV-45 13 4.1 9.4 11.7 1.1 2.2 6.3
HPV-51 7 2.2 5.1 6.3 0.8 0.6 3.8
HPV-52 58 18.3 42.0 52.3 2.1 14.2 22.4
HPV-56 8 2.5 5.8 7.2 0.9 0.9 4.4
HPV-58 28 8.8 20.3 25.2 1.6 5.7 12.0
HPV-59 6 1.9 4.3 5.4 0.7 0.6 3.5
Probable high-risk HPV genotype
HPV-66 25 7.9 18.1 54.3 1.5 5.3 11.1
HPV-68 26 8.2 18.8 56.5 1.5 5.7 11.4
Low-risk HPV genotype
HPV-6/11 3 0.9 2.2 5.6 0.6 0.0 2.2
HPV-42 30 9.5 21.7 55.6 1.6 6.3 12.9
HPV-43 17 5.4 12.3 31.5 1.3 2.8 8.2
HPV-44 7 2.2 5.1 13.0 0.8 0.6 3.8
Vaccine covered genotypes
HPV 16/18 26 8.2 1.6 5.0 11.7
HPV 6/11/16/18 29 9.1 1.7 6.0 12.6
HPV 6/11/16/18/31/33/45/52/58 90 28.4 2.5 23.3 33.2
  1. *Because of the possibility of multiple infections, women may be counted more than once
  2. aPercentages calculated using the total number of cases (N=317) as a common denominator
  3. bPercentages calculated using the number of positive cases (N=138) as a common denominator
  4. cPercentages calculated using the number of positive cases among the risk category as a common denominator